Rituximab and fludarabine produce long-term remissions in CLL
Friday, February 25, 2011 - 10:00
in Health & Medicine
New research shows that a less-toxic combination of a targeted immune-based drug and a chemotherapy drug can produce long-term remissions in some chronic lymphocytic leukemia patients. And it does so without increasing the risk of later therapy-related myelodysplastic syndrome and acute myeloid leukemia, which can often occur with a three-drug combination used to treat these patients.